Clinical Trials Logo

Epileptic Syndromes clinical trials

View clinical trials related to Epileptic Syndromes.

Filter by:

NCT ID: NCT06388174 Recruiting - Epilepsy Clinical Trials

Idiopathic Generalized Epilepsy Syndromes

Start date: January 1, 2023
Phase:
Study type: Observational

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance. According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

NCT ID: NCT06223334 Recruiting - Epileptic Syndromes Clinical Trials

Epileptic Syndromes in Infants and Early Childhood

Start date: October 1, 2023
Phase:
Study type: Observational

To evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.

NCT ID: NCT06222840 Completed - Epileptic Syndromes Clinical Trials

Electro-clinical Features and Functional Connectivity Analysis in SYN1 Gene Mutation-related Epilepsy

Start date: April 1, 2023
Phase:
Study type: Observational

SYN1 gene mutation is an X-linked gene mutation that causes numerous pathological manifestations such as seizures and neurodevelopmental disorders. A few descriptions of this disease have been published in the last decade, but the electro-clinical features of epilepsy are still largely unknown. No analysis of electroencephalographic connectivity has yet been performed. The aim of this study is to perform a detailed electro-clinical seizure analysis and electroencephalographic analysis in patients with a SYN1 gene mutation, in an attempt to identify a characteristic pattern that would allow earlier diagnosis and better understanding and management of this disease.

NCT ID: NCT05885646 Recruiting - Clinical trials for Epilepsy in Children

Effect of Sulthiame on EEG in Childhood Epilepsy Syndromes

SURF
Start date: October 18, 2023
Phase:
Study type: Observational

The effect of sulthiame on EEG has been studied in epilepsy syndromes of childhood with sleep activation by comparing sleep EEG obtained at baseline and after 4 weeks of treatment. The aim of the study is to know if an effect is still identifiable after 2 weeks of treatment by performing sleep EEG recordings after 2 and 4 weeks of treatment, respectively.

NCT ID: NCT05571371 Not yet recruiting - Clinical trials for MCP-2: Monocyte Chemo-attractant Protein-2

Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure

seizure
Start date: October 2022
Phase:
Study type: Observational

1. Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. 2. Possible role to predict the prognosis of patients with epileptic seizure.

NCT ID: NCT05241678 Completed - Clinical trials for Epilepsy, Generalized

Evaluation of the 24/7 EEG™ SubQ System in Subjects With Uncontrolled Genetic Generalised Epilepsy Syndrome

Start date: February 15, 2022
Phase:
Study type: Observational [Patient Registry]

This study is a 12 week prospective, comparative investigation in subjects diagnosed with uncontrolled genetic generalised epilepsy (GGE) also known as idiopathic generalised epilepsy (IGE). The purpose of the study is to evaluate whether the 24/7 EEG™ SubQ system, a subcutaneous implantable device, will demonstrate seizure sensitivity approximating that of inpatient video-EEG monitoring with the standard 10-20 electrode system.

NCT ID: NCT05126914 Not yet recruiting - Epilepsy Clinical Trials

Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents

EPIRARE
Start date: December 2021
Phase:
Study type: Observational

Rare epilepsies as a whole account for 20-30% of epilepsies, but knowledge about prognostic factors is currently limited. This means that it is difficult to provide adequate information to families at diagnosis and during follow-up. Prognostic factors are also important for management as they can have an impact on the patient's outcome (time to intervention, choice of one molecule over another, etc.). Finally, few treatments are currently available for these epilepsies. One of the limitations to the development of treatments is the lack of real life data as it is difficult to create reliable primary endpoints such as the rate of patients becoming seizure free naturally compared to a therapeutic intervention. The aim of this real-life study is to evaluate the response to treatment as well as to see the evolution of cognitive and psychiatric comorbidities. As explained above, there are very few randomised trials except for 3 rare epilepsies (infantile spasm syndrome, Dravet syndrome, Lennox-Gastaut syndrome). This has led to the virtual absence of management recommendations, including for the three syndromes mentioned above, where attempts at treatment algorithms have been proposed, although these have not been able to be considered as evidence-based recommendations. As a result, there is some diversity in the management of rare epilepsies from one centre to another. However, this diversity in management can be an asset in a real-life study. This will make it possible to compare different management methods, both in terms of seizure control and medium-term outcome.

NCT ID: NCT05097742 Completed - Epilepsy Syndrome Clinical Trials

Cognitive Impairments in Children With Epilepsy

Start date: October 15, 2021
Phase:
Study type: Observational

Since the proportion of language and attentional difficulties in patients with epilepsy is recognized, both in the literature and in the clinical experience of practitioners, it is appropriate to propose a complete speech-language assessment of oral language and attention.This study investigates these impairments through the taking of specific tests. The general objective of this study is to observe possible oral language and attention disorders in children with epilepsy, by age and etiology of epilepsy. The objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.

NCT ID: NCT04912856 Terminated - Epilepsy Clinical Trials

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

EPIK-OLE
Start date: August 17, 2021
Phase: Phase 3
Study type: Interventional

To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).

NCT ID: NCT04639310 Terminated - Epilepsy Clinical Trials

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

EPIK
Start date: March 29, 2021
Phase: Phase 3
Study type: Interventional

To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).